Table 2.
Characteristics of the total study population subdivided by year of diagnosis
| Year of diagnosis N (%) |
|||||||
|---|---|---|---|---|---|---|---|
| Total population 1755 |
1989–1993 283 |
1994–1998 240 |
1999–2003 273 |
2004–2008 296 |
2009–2013 319 |
2014–2018 343 |
|
| Mean age (range) | 55 (9–97) | 55 (11–88) | 56 (14–86) | 54 (9–88) | 55 (10–87) | 54 (9–87) | 56 (11–97) |
| Sex | |||||||
| Male | 1256 (71) | 208 (73) | 176 (73) | 203 (74) | 206 (70) | 224 (70) | 239 (70) |
| Female | 499 (28) | 75 (27) | 64 (27) | 70 (25) | 90 (30) | 96 (30) | 104 (30) |
| T stage | |||||||
| Tx | 88 (5) | 24 (9) | 17 (7) | 23 (9) | 11 (4) | 9 (3) | 2 (1) |
| T0 | 1 (< 1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) |
| T1/T2 | 798 (45) | 114 (40) | 81 (34) | 135 (49) | 151 (51) | 155 (48) | 162 (47) |
| T3/T4 | 868 (50) | 145 (51) | 142 (59) | 115 (42) | 134 (45) | 156 (49) | 176 (52) |
| N stage | |||||||
| Nx | 71 (4) | 20 (8) | 12 (6) | 15 (5) | 9 (3) | 10 (3) | 5 (1) |
| N0 | 377 (21) | 71 (26) | 57 (24) | 57 (21) | 61 (21) | 62 (20) | 69 (20) |
| N1 | 396 (22) | 35 (13) | 29 (13) | 64 (23) | 78 (26) | 87 (27) | 103 (30) |
| N2 | 721 (41) | 123 (44) | 107 (45) | 105 (38) | 119 (40) | 127 (40) | 122 (36) |
| N3 | 190 (11) | 24 (9) | 27 (12) | 32 (12) | 29 (10) | 34 (10) | 44 (13) |
| M stage | |||||||
| M0/x | 1657 (94) | 273 (96) | 231 (96) | 255 (94) | 280 (95) | 298 (93) | 312 (92) |
| M1 | 98 (6) | 10 (4) | 9 (4) | 15 (6) | 15 (5) | 21 (7) | 28 (8) |
| Tumor stage | |||||||
| I | 91 (5) | 12 (4) | 10 (4) | 11 (4) | 13 (4) | 16 (5) | 19 (8) |
| II | 270 (15) | 16 (6) | 11 (5) | 63 (23) | 66 (22) | 57 (18) | 57 (17) |
| III | 467 (27) | 43 (15) | 33 (14) | 86 (31) | 90 (31) | 113 (35) | 102 (30) |
| IV | 894 (51) | 202 (71) | 183 (76) | 103 (38) | 114 (42) | 130 (41) | 152 (44) |
| Unknown | 33 (2) | 10 (4) | 3 (1) | 10 (4) | 3 (1) | 4 (1) | 3 (1) |
| Pathological classification | |||||||
| WHO type I | 208 (12) | 41 (14) | 32 (13) | 24 (10) | 27 (9) | 46 (15) | 38 (11) |
| WHO type II | 347 (20) | 33 (11) | 38 (16) | 41 (14) | 62 (20) | 70 (22) | 103 (30) |
| WHO type III | 981 (56) | 175 (62) | 128 (53) | 166 (61) | 179 (61) | 174 (54) | 159 (46) |
| Basaloid | 12 (< 1) | 0 (0) | 2 (1) | 4 (1) | 2 (1) | 2 (1) | 2 (1) |
| NOS | 207 (12) | 34 (13) | 40 (17) | 39 (14) | 26 (9) | 27 (8) | 41 (12) |
| EBV status | |||||||
| Positive | 650 (37) | 2 (1) | 21 (9) | 82 (30) | 149 (50) | 184 (57) | 212 (62) |
| Negative | 154 (9) | 2 (1) | 6 (3) | 11 (4) | 23 (8) | 44 (15) | 68 (20) |
| Unknown | 952 (54) | 279 (98) | 213 (89) | 180 (66) | 124 (41) | 92 (28) | 63 (18) |
EBV Epstein–Barr virus, NOS not otherwise specified, WHO World Health Organization